November 5, 2008
Y’s Therapeutics Announces Acceptance of CTA to conduct Phase I/II Clinical Trial of YSCMA in France
September 16, 2008
Y's Therapeutics Completes Phase IIa Trial with YSPSL in Kidney Transplant Patients for Prevention of Ischemic Reperfusion Injury (IRI)
September 10, 2008
Conclusion of Exclusive Licensing Agreement of YSCMA, Humanized Anti-CD26 Monoclonal Antibody, for Development and Sales in Japan
April 4, 2008
In appointing about the Board of directors and the Auditors
February 14, 2008
Y's Therapeutics announces FDA acceptance of IND to conduct Phase I clinical trial for YSCMA in the USA
January 15, 2008
We have update the employment information at the our website.
More
Top
|
Site Map
|
Access Map
|
Privacy Policy
|
Terms of Use
